HIV-1 superinfection resembles primary infection. by Sheward, Daniel J. et al.
B R I E F R E P O R T
HIV-1 Superinfection Resembles
Primary Infection
Daniel J. Sheward,1 Roman Ntale,1,2 Nigel J. Garrett,3,4 Zenda L. Woodman,5
Salim S. Abdool Karim,3,7 and Carolyn Williamson1,3,6
1Division of Medical Virology, Institute of Infectious Diseases and Molecular
Medicine, University of Cape Town, South Africa; 2Department of Biomedical
Laboratory Sciences, College of Medicine and Health Sciences, Kigali, Rwanda;
3Centre for the AIDS Programme of Research in South Africa (CAPRISA),
4Department of Infectious Diseases, Nelson R. Mandela School of Medicine,
University of KwaZulu–Natal, Durban, 5Department of Molecular and Cell Biology,
University of Cape Town, and 6National Health Laboratory Services, Johannesburg,
South Africa; and 7Department of Epidemiology, Mailman School of Public Health,
Columbia University, New York, New York
The relevance of superinfection as a model to identify corre-
lates of protection against human immunodeficiency virus
(HIV) depends on whether the superinfecting transmission
resembles primary infection, which has not been established.
Here, we characterize the genetic bottleneck in superinfected
individuals for the first time. In all 3 cases, superinfection
produced a spike in viral load and could be traced to a single,
C-C chemokine receptor 5–tropic founder virus with shorter,
less glycosylated variable regions than matched chronic virus-
es. These features are consistent with primary HIV transmis-
sion and provide support for the use of superinfection as a
model to address correlates of protection against HIV.
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A significant challenge facing the development of a human im-
munodeficiency virus (HIV) vaccine is that correlates of protec-
tion against HIV are not clearly defined. Vaccine efficacy trials
are time consuming and expensive, and models that increase
our understanding of correlates of protection can potentially ac-
celerate vaccine development. By definition, in HIV superinfec-
tion a secondary acquisition of HIV occurs in the face of an
ongoing anti-HIV immune response and therefore provides a
unique opportunity to assess whether the immune responses
typically elicited during natural HIV infection provide any pro-
tection against subsequent HIV infection. Indeed, several stud-
ies have compared immunological markers in superinfected
participants to those who were presumably exposed but not su-
perinfected [1–4]. However, the utility of superinfection as a
challenge model depends on whether superinfection resembles
primary transmission, which has not yet been established.
Primary HIV sexual transmission results in a severe genetic
bottleneck associated with the acquisition of HIV. It is estimated
that during the sexual transmission of HIV, approximately 80% of
infections are the result of a single founder variant, despite expo-
sure to hundreds to millions of virions in the inoculum [5–7].
These transmitted/founder (T/F) viruses are consistently C-C
chemokine receptor 5 (CCR5)–tropic, and it has been shown else-
where that subtype C has shorter, less glycosylated envelopes than
viruses collected during chronic infection [8]. However, the genet-
ic bottleneck associated with superinfection and the question of
whether the superinfecting viruses have phenotypes typical of pri-
mary viruses have not been studied, to our knowledge. Here, we
characterize the genetic bottleneck in three superinfected individ-
uals, and characterize the features of the T/Fs of superinfection.
Methods
Longitudinal samples were provided by participants in the
CAPRISA [Centre for the AIDS Programme of Research in
South Africa] 002 Acute Infection Study (n = 62). Plasma sam-
ples were taken weekly for the first 3 weeks after primary infec-
tion, fortnightly until approximately 3 months after primary
infection, monthly until approximately 1 year after primary in-
fection, and quarterly thereafter (described in detail in [9]).
Written informed consent was obtained from all participants,
and ethical approval for the study was granted by the University
of KwaZulu-Natal (E013/04), University of Cape Town (025/
2004), and University of the Witwatersrand (M040202).
Putative cases of superinfection were identified retrospective-
ly by the presence of divergent variants (DNA distance >5%) in
previously generated sequences. If contamination could not ad-
equately explain the divergent sequences, additional env
sequences were generated from longitudinal plasma samples
by single-genome amplification (SGA) and, in the case of
CAP256, strain-specific polymerase chain reaction (PCR).
Plasma viral RNA was extracted from 200L or 400 µL of
plasma using either the Roche MagNApure (Roche Applied Sci-
ence) or Qiagen viral RNA extraction kits (Qiagen). RNA was
reversed-transcribed to complementary DNA (cDNA), using
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Superscript III (Invitrogen, Life Technologies), as described else-
where [7].
Envelope cassettes were amplified from the full-length cDNA
in nested PCR by SGA using a Platinum Taq High Fidelity kit
(Invitrogen, Life Technologies), as described elsewhere [7].
Briefly, cDNA was serially diluted until <30% of the reactions
were PCR positive, such that >80% of the amplicons, according
to a Poisson distribution would probably have been amplified
from a single template. This approach prevents template resam-
pling and PCR-induced recombination that can occur if multi-
ple templates are amplified in a reaction. Primers used in the
outer reaction were Vif1 (5′-GGGTTTATTACAGGGACAG
CAGAG-3′; HXB2 nucleotides 4900–4923) and OFM19
(5′-GCACTCAAGGCAAGCTTTATTGAGGCTTA-3′; HXB2
nucleotides 9604–9632). Inner primers used were ENV1A-Rx
(5′-CACCGGCTTAGGCATCTCCTATAGCAGGAAGAA-3′;
HXB2 nucleotides 5954–5982) and EnvN (5′-TTGCCAAT
CAAGGAAGTAGCCTTGTGT-3′; HXB2 nucleotides 9145–
9171). For strain-specific SGA the CAP256 superinfecting
virus at select time points, reverse transcription was performed
using a primer specific for the superinfecting variant (256spR
5′-CTCCCTCTGCTGTTGGCTGCGCTCGCGC-3′; HXB2
nucleotides 8856–8884) as the antisense primer in both rounds
of amplification [10]. Outer reaction thermal cycling conditions
were as follows: initial denaturation at 94°C for 2 minutes, fol-
lowed by 35 cycles (94°C for 15 seconds, 55°C for 30 seconds,
68°C for 4 minutes), followed by a final extension for 1 cycle
(68°C for 20 minutes). Inner reaction thermal cycling condi-
tions were the same as above, for 45 cycles.
To refine the estimates of the timing of superinfection and
differentiate the transmission of one virus or multiple viruses,
we estimated the time to the MRCA of multiple closely related
sequences generated from the first time point when superinfec-
tion was detectable. The time to the MRCA was then estimated
with Poisson Fitter software (http://www.hiv.lanl.gov/content/
sequence/poisson_ fitter/poisson_fitter/html), using a mutation
rate of 2.16 × 10–05 mutations per base pair (bp) per cycle and a
generation time of 2 days. Sequences were determined to have
originated from a single T/F virus if they displayed a star phy-
logeny and the number of mutations conformed to a Poisson
distribution (described in detail in [6]).
Variable region lengths and the number of potential aspara-
gine (N)–linked glycosylation sites were calculated using an
in-house script. The V1, V2, V3, V4, and V5 regions were mea-
sured from HXB2 positions 126–157, 158–196, 296–331, 385–
418 and 460–471 respectively, and summed. Potential N-linked
glycosylation sites were identified within the variable regions by
the presence of sequons (N-X-S/T, where X is any amino acid
except proline). Overlapping sequons (NNST, NNSS, NNTT,
and NNTS) were counted as a single N-linked glycosylation site.
The length and glycosylation of the variable regions in super-
infecting viruses were compared with those in viruses from
primary infection and consensus sequences from 3 years after
infection (chronic infection), using an unpaired, 2-tailed
t test. The acute and chronic infection groups represented all
participants in the CAPRISA 002 cohort for whom env SGA se-
quences were already available from both acute infection and 3
years after infection. Consensus sequences for chronic infection
were derived according to “majority rules” from a median of 10
sequences from each individual (range, 5–24). The length and
glycosylation of the variable regions in matched acute and
chronic sequences were compared using a 2-tailed, paired t
test implemented in Prism 5 software (GraphPad Software).
To determine whether the superinfecting sequences harbored
recombinant regions inherited from primary viruses, we calcu-
lated Smith-Waterman similarities over a 100-bp sliding win-
dow (5-bp step size), using an in-house script. Similarities of
the superinfecting virus to the primary infecting viruses were
compared with similarities to viruses from a panel of geograph-
ically matched env sequences (n = 68). A similarity score of
≥98% for the primary infecting virus but not for any of the
panel viruses (over ≥3 consecutive windows) was considered
evidence of recombination. An example of a detectable case
of recombination is shown in Supplementary Figure 1. Corecep-
tor tropism was predicted using the Geno2pheno [11] Web
server (http://coreceptor.geno2pheno.org/), with a false-positive
rate cutoff of 10%.
RESULTS
Longitudinal gag (n = 365), nef (n = 289), and/or env (n = 2011)
single-genome sequences were available from 32 participants in
the CAPRISA 002 cohort over a total of 54.9 person-years of fol-
low-up [7, 12–14] (R. Thebus, B. Lambson, unpublished data).
These sequences were screened retrospectively for superinfec-
tion, defined as infection after seroconversion with a second
variant that is separated phylogenetically from the primary in-
fecting virus by epidemiologically unlinked viruses (phyloge-
netically unlinked). For 3 participants (CAP237, CAP256, and
CAP281), a phylogenetically unlinked virus could be detected
after seroconversion that was not detectable at or before sero-
conversion (Figure 1A–D). We performed SGA and strain-
specific PCR on sequential plasma samples and sequencing to
confirm superinfection and to identify the timing.
In all 3 cases, the time between sequential plasma samples
that tested negative and then positive for the superinfecting
virus could be narrowed to within 2–6 weeks. To determine
the multiplicity of superinfection and to accurately identify
the founder(s) of superinfection, we analyzed 5–11 superinfect-
ing single-genome env sequences generated from the first plas-
ma sample with evidence of the superinfecting virus. For
CAP237 and CAP281, these were generated without the need
for strain-specific primers. In all 3 cases, the early sampled
superinfecting viral population was highly homogenous, with
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single-genome env sequences differing from each other by ≤2
mutations (Figure 1E–G: see insets). The superinfecting se-
quences in all 3 participants conformed to a star phylogeny
with a Poisson distribution of mutations, consistent with super-
infection being the result of a single T/F virus.
To ensure that the inferred T/F represented the superinfect-
ing virus before any recombination with the primary virus, we
looked for regions within the superinfecting sequences that
were more similar to the primary virus than they were to a
panel of geographically matched sequences using sliding win-
dow similarity measures. In all 3 cases, there was no significant
evidence of recombinant regions inherited from the primary
virus (Figure 1E–G). The consensus/MRCA was therefore con-
sidered an accurate representation of the superinfecting T/F
virus. The 3 superinfecting viruses were all classified as subtype
C, were computationally predicted by Geno2pheno to be CCR5
tropic, and differed from the primary infecting variants (also all
subtype C) across env by 12.53% (CAP237), 11.92% (CAP256),
and 13.99% (CAP281).
To refine the likely window of superinfection, we estimated
the time from a most recent common ancestor of the early
(highly homogenous, nonrecombinant) superinfecting se-
quences. The timing of superinfection for CAP237, CAP256,
and CAP281 was estimated as 9 (range, 6–11), 13 (11–14),
and 42 (40–44) weeks after infection, respectively. In all 3
cases, this inferred time of superinfection preceded a >10-fold
spike in viral load (Figure 1B–D). Similar spikes in viral load
(>10-fold increase from the previous visit), outside of acute in-
fection, were observed only infrequently in the other 29 partic-
ipants (1 spike per 13 person-years of follow-up).
Figure 1. Identification of the transmitted/founder superinfecting envelopes, before recombination with the primary virus. A, Maximum likelihood phy-
logeny depicting the presence of 2 strains separated phylogenetically by epidemiologically unlinked viruses in participants CAP237 (circles), CAP256 (tri-
angles), and CAP281 (squares). The phylogeny was reconstructed using env sequences from CAP237, CAP256, CAP281 along with 58 subtype C sequences
from 30 individuals, including 24 participants from the CAPRISA [Centre for the AIDS Programme of Research in South Africa] 002 cohort. B–D, Viral load
(solid black lines) and CD4 cell counts (dotted gray lines) over time are shown for the 3 superinfected participants: CAP237 (B), CAP256 (C), and CAP281 (D).
The limit of detection for the viral load assay was 400 copies/mL. In each case, the detection (+) or absence (−) of the superinfecting virus in sequences
from single-genome amplification (SGA) and strain-specific polymerase chain reaction (ssPCR) is indicated. The estimated window of superinfection is
shown, based on the 95% confidence interval for the estimated time since a most recent common ancestor (tMRCA) for the early (nonrecombinant) su-
perinfecting viral sequences. ART, initiation of antiretroviral therapy. E–G, Similarity of the consensus of the early superinfecting env sequences from
CAP237 (E ), CAP256 (F ), and CAP281 (G), to sequences from an alignment of subtype C sequences (including sequences from the CAPRISA 002 cohort
and the primary infecting viruses). Over all windows (100–base pair [bp] windows with a 5-bp shift), the superinfecting viruses are not more similar to the
primary virus (black line) than would be expected for unlinked sequences (gray lines), indicating the absence of recombinant regions inherited from the
primary virus. Insets depict highlighter plots of the early single-genome env sequences of the superinfecting viral populations indicative of a “star” phy-
logeny of near identical sequences in each case.
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Recently transmitted subtype C viruses seem to possess
shorter, less glycosylated variable regions than viruses from
chronic infection [8]. To establish whether superinfecting foun-
der viruses had similar characteristics, we compared the length
and potential N-linked glycosylation of the variable regions
with a panel of matched acute and chronic subtype C sequences
from the same cohort, sampled over a similar period. There was
no variance in variable region length or number of N-linked
glycosylation sites among the sampled early superinfecting
quasispecies within participants. env SGA sequences for acute
infection were available from 21 participants in the CAPRISA
002 cohort, of whom 16 had matched SGA sequences available
3 years after infection. Consistent with previous observations,
viruses sampled 3 years after infection had longer (P = .001),
potentially more glycosylated (P = .01) variable regions com-
pared with those sampled shortly after transmission. Super-
infecting viruses had characteristics typical of recently
transmitted viruses, with length and potential N-linked glyco-
sylation significantly lower than in viruses sampled 3 years
after infection (P = .007 and P = .01, respectively; Figure 2).
DISCUSSION
Since the first case report in 2002 [15], individuals with HIV
superinfection are increasingly being identified. The implica-
tion is that the natural immune response to HIV infection is
frequently not sufficient to provide protection from infection
with another HIV variant, raising concerns for vaccine design.
Even if the immune responses generated during natural infec-
tion provide no protection from HIV infection, quantifying
these responses at the time of superinfection will still address
an important question, namely: what is not sufficient to provide
protection? However, the utility of superinfection as a model of
vaccine protection depends on the ability of the superinfection
event to accurately reflect primary infection, though this has not
previously been demonstrated, to our knowledge.
Here, we characterized the multiplicity of infection for a su-
perinfecting strain for the first time. Frequent sampling allowed
us to show that 3 cases of superinfection were all probably es-
tablished by a single virus. This is consistent with primary HIV
infection, in which clinical infection is established by a single
founder virus in approximately 80% of individuals [6, 7].
With the limited sequencing depth, it remains possible that
we failed to detect minority superinfecting variants. It is also
possible that the use of strain-specific primers for CAP256
failed to amplify other superinfecting variants. Nevertheless,
our data are consistent with a severe genetic bottleneck after
superinfection. We also showed that superinfection was fol-
lowed by a spike in viral load and that the superinfecting viruses
were predicted to be CCR5 tropic and had shorter, less glycosy-
lated variable regions than variants from chronic infection;
characteristics of recently transmitted viruses. These data indi-
cate that superinfection transmission resembles primary sexual
transmission, providing support for superinfection as a model
to address correlates of protection against HIV.
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